TScan Therapeutics Announces Upcoming Presentation at the TD Cowen 45th Annual Health Care Conference

Rhea-AI Summary

TScan Therapeutics (Nasdaq: TCRX), a clinical-stage biotech company developing TCR-engineered T cell therapies for cancer treatment, has announced its participation in the TD Cowen 45th Annual Health Care Conference. The presentation is scheduled for March 5, 2025, at 1:10 p.m. Eastern Time at the Marriott Copley Place in Boston, MA.

Investors and interested parties can access the presentation through a webcast available on the 'Events and Presentations' section of TScan's website at ir.tscan.com. The webcast recording will remain accessible on the company's website for 90 days after the event.

WALTHAM, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the Company will present at the TD Cowen 45^th Annual Health Care Conference being held at the Marriott Copley Place in Boston, MA on Wednesday, March 5, 2025 at 1:10 p.m. Eastern Time.

A webcast of the presentation will be available on the “Events and Presentations” section of the Company’s website at ir.tscan.com. An archived replay of the webcast will be available on the Company’s website for 90 days following the event.

About TScan Therapeutics, Inc.

TScan is a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidates are in development for the treatment of patients with hematologic malignancies to prevent relapse following allogeneic hematopoietic cell transplantation (the ALLOHA™ Phase 1 heme trial). The Company has developed and continues to expand its ImmunoBank, the Company’s repository of therapeutic TCRs that recognize diverse targets and are associated with multiple HLA types, to provide customized multiplex TCR-T therapies for patients with a variety of cancers (the PLEXI-T™ Phase 1 solid tumor trial). The Company is currently enrolling patients into both clinical programs.

Contacts

Heather Savelle
TScan Therapeutics, Inc.
VP, Investor Relations
857-399-9840
hsavelle@tscan.com 

Maghan Meyers
Argot Partners
212-600-1902
TScan@argotpartners.com

FAQ

When is TScan Therapeutics (TCRX) presenting at the TD Cowen Healthcare Conference 2025?

TScan Therapeutics will present on March 5, 2025, at 1:10 p.m. Eastern Time at the Marriott Copley Place in Boston, MA.

How long will TScan Therapeutics' (TCRX) TD Cowen conference webcast be available?

The webcast replay will be available on TScan's website for 90 days following the event.

Where can I watch TScan Therapeutics' (TCRX) TD Cowen conference presentation?

The presentation webcast will be available on TScan's investor relations website at ir.tscan.com under the 'Events and Presentations' section.

What type of therapies is TScan Therapeutics (TCRX) developing?

TScan Therapeutics is developing T cell receptor (TCR)-engineered T cell (TCR-T) therapies for cancer treatment.